Board of Directors
Introduction
The Board of Directors of Sonova Holding AG sets the overall direction and supervision of the management (see Art. 716a para. 1 of the Swiss Code of Obligations). Its working methods are reflected in the Organizational Regulations and the Board Committee Charters (available for the Audit Committee and the Nomination and Compensation Committee).
As determined in Art. 1 of the Organizational Regulations, the Board of Directors plans the succession of its members and defines the criteria for selecting candidates so that the composition is well-balanced in terms of size, professional skills, international experience, and diversity. Sonova ensures that newly elected members receive an appropriate introduction and orientation and that the members of the Board of Directors receive continuing training with respect to their responsibilities.
Board of Directors independence
Members of the Board of Directors are considered to be independent, according to Section 15 of the Swiss Code of Best Practice for Corporate Governance and Art. 6 lit. c of the Organizational Regulations, if they personally or in association with related persons have not been a member of the Management Board during the last three years, have not served as lead auditor of external auditor during the last two years, and have no or only comparatively minor business relations with the company. According to these rules, all members of Sonovaʼs Board of Directors are considered to be independent.
Board of Directors fees
Fees for members of the Board of Directors are structured to be consistent with the principle of independence; members therefore only receive fixed fees paid in the form of a cash retainer and non-discounted shares with a blocking period of five years and four months (Chair of the Board of Directors) or four years and four months (all other members of the Board of Directors). The allocation of shares strengthens alignment with shareholdersʼ interests. In addition, members of the Board of Directors receive committee retainers for their services on Sonovaʼs committees. Members of the Board of Directors do not receive performance-related compensation, severance payments, or benefits (please see the relevant chapters in the compensation report for more information).
Executive management positions
No member of the Board of Directors holds an executive management position with Sonova Holding AG or any of its subsidiaries and has not done so in the past three years.
Business connections of members of the Board of Directors with Sonova Holding AG or its subsidiaries
In the 2024/25 financial year, there were no business connections between individual members of the Board of Directors, including companies or organizations represented by them, and Sonova Holding AG or its subsidiaries.
Other activities and vested interests
Except as disclosed in the biographies of the members of the Board of Directors, no member of the Board of Directors holds any position in a governing or supervisory body of any important private or public sector organization, institution, or foundation; none holds any permanent management or consultancy position with an important interest group, or any public or political office.
Mandates outside Sonova Holding AG
No member of the Board of Directors may hold more than four mandates in listed companies and no more than five mandates in other companies and organizations. Mandates shall mean mandates in comparable functions at other enterprises as well as in (trading) associations, organizations, foundations and similar legal entities with an economic purpose.
The following mandates are not subject to these limitations:
- Mandates in companies which are controlled by Sonova or in companies which control Sonova; and
- Mandates held at the request of Sonova or companies controlled by Sonova, whereby no member of the Board of Directors may hold more than ten such mandates.
For further details see Art. 30 of the Articles of Association, and the compensation report for outside mandates to be disclosed under the Swiss Code of Obligations.
Board of Directors competence and evaluation
The Nomination and Compensation Committee and the Board of Directors evaluate current and prospective members according to a skills and experience competency matrix to ensure that an appropriate mix of relevant skills and experience is represented in the Board of Directors. The matrix includes criteria relating to executive management expertise, board experience, relevant industry know-how, strategic thinking (including M&A), international/regional experience, technology/product development experience (hardware and software), digital expertise, IT expertise, Supply Chain Management expertise, financial expertise, sales/marketing expertise, retail and service expertise, HR expertise, and ESG expertise. When following the matrix criteria in the nomination and evaluation processes, the Nomination and Compensation Committee and the Board of Directors are committed to considering characteristics including but not limited to, gender, age, nationalities or country of origin, ethnicity, cultural background, ways of believing and mindsets, in order to establish balance in terms of diversity and inclusion
The Nomination and Compensation Committee and the Board of Directors make use of this information to identify potential gaps, and to help create profiles for new director searches.
The Board of Directors also conducts an annual self-assessment to:
- Ensure and enhance its comprehensive understanding of the business and the company;
- Evaluate the work of the Board of Directors, its committees, the individual members of the Board of Directors, and the Chair;
- Make the best use of the human capital represented on the Board of Directors; and
- Optimize efficiency, effectiveness of working methods, and cooperation among members of the Board of Directors and members of the Management Board.
The Chair of the Board of Directors initiates the annual Board of Directors self-assessment by distributing an evaluation questionnaire, previously approved by the Board of Directors. The Chair of the Board of Directors is responsible for collecting the assessments and for initiating the review of the consolidated results by the Nomination and Compensation Committee and subsequently the full Board of Directors.
Composition of the Board of Directors
As of March 31, 2025, the composition of the Board of Directors is as follows:
Robert F. Spoerry | Stacy Enxing Seng | Gilbert Achermann | Gregory Behar | Lynn Dorsey Bleil | Lukas Braun-schweiler | Roland Diggelmann | Julie Tay | Ronald van der Vis | Adrian Widmer | |||||||||||
Age | 69 | 60 | 61 | 55 | 61 | 68 | 57 | 58 | 57 | 56 | ||||||||||
Tenure (years) | 22 | 11 | 1 | 4 | 9 | 7 | 4 | 3 | 16 | 5 | ||||||||||
Gender | ||||||||||||||||||||
Female | x | x | x | |||||||||||||||||
Male | x | x | x | x | x | x | x | |||||||||||||
Race/Ethnicity | ||||||||||||||||||||
White | x | x | x | x | x | x | x | x | x | |||||||||||
Non-White | x | |||||||||||||||||||
Committee Member | ||||||||||||||||||||
Audit | x | x | x | x | ||||||||||||||||
Nomination & Compensation | x | x | x | x | ||||||||||||||||
Independent | x | x | x | x | x | x | x | x | x | x |
Elections, terms of office, and biographies
Election procedure and limits on the terms of office
Art. 16 para. 1 of the Articles of Association of Sonova Holding AG states that the Board of Directors must consist of a minimum of five and a maximum of ten members. The members of the Board of Directors are elected by the shareholders at the General Shareholdersʼ Meeting (Art. 10 no. 2 of the Articles of Association).
Re-elections for successive terms are possible. Members of the Board of Directors shall retire automatically at the first General Shareholdersʼ Meeting following their seventieth birthday. In justified individual cases, the Board of Directors may make an exemption. For further details see Art. 6 of the Organizational Regulations.
First election and remaining term of office
The following table shows the date of the first election for each member of the Board of Directors. The Articles of Association require that the term of office of a member of the Board of Directors ends after the completion of the next Annual General Shareholdersʼ Meeting. As a consequence, each such member will have to be re-elected annually at the Annual General Shareholdersʼ Meeting. All members of the Board of Directors were re-elected by the 2024 Annual General Shareholdersʼ Meeting, except Gilbert Achermann, who was initially elected at that meeting.
Name | Position | First elected | ||
Robert F. Spoerry | Chair | 2003 | ||
Stacy Enxing Seng | Vice Chair | 2014 | ||
Gilbert Achermann | Member | 2024 | ||
Gregory Behar | Member | 2021 | ||
Lynn Dorsey Bleil | Member | 2016 | ||
Lukas Braunschweiler | Member | 2018 | ||
Roland Diggelmann | Member | 2021 | ||
Julie Tay | Member | 2022 | ||
Ronald van der Vis | Member | 2009 | ||
Adrian Widmer | Member | 2020 |

Robert F. Spoerry
(born 1955, Swiss citizen) has been Chair of the Board of Directors of Sonova Holding AG since March 30, 2011, and a non-executive member of the Board of Directors since 2003.
Robert F. Spoerry is also the non-executive Chair of the Board of Directors of Mettler Toledo International Inc., a leading global manufacturer and marketer of precision instruments and related services for use in laboratory, manufacturing, and food retailing applications. He joined Mettler Toledo in 1983 and was CEO from 1993 to 2007. He led the buyout of Mettler-Toledo from Ciba-Geigy in 1996, and the companyʼs subsequent Initial Public Offering on the New York Stock Exchange (NYSE) in 1997. From 1998 until May 2024, he was Chair of the Board of Directors of Mettler-Toledo International Inc.
His long-standing experience in the technology sector, his deep knowledge of Sonova and his strong technical background with innovation-driven companies provides a substantial benefit to the Group and its shareholders. Robert F. Spoerry devotes a substantial amount of his time to his service as Chair of the Board of Directors.
Robert F. Spoerry graduated in mechanical engineering from the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland, and holds an MBA from the University of Chicago, USA.
Outside mandates
Listed companies:
- Member of the Board of Directors of Bystronic Holding AG (former Conzetta Holding AG)
Other mandates:
- n.a.

Stacy Enxing Seng
(born 1964, US citizen) has been a non-executive member of the Board of Directors since 2014 and serves on the Nomination and Compensation Committee. She became Vice Chair of the Board of Directors at the 2021 AGM.
She previously served as President of Covidienʼs Vascular Therapies division. Stacy Enxing Seng joined Covidien as president of its vascular therapies division in July 2010 through its acquisition of ev3 where she was a founding member and executive officer responsible for leading ev3’s Peripheral Vascular Division from inception. She has also held various positions at Boston Scientific, SCIMED Life Systems Inc., Baxter Healthcare, and American Hospital Supply.
With her broad experience in the medical technology sector and her strong track record in growing startups and leading multinational companies, she brings further important perspectives to the Group. Her expertise in working with regulatory agencies around the globe brings valuable insight to the Board of Directors.
Stacy Enxing Seng received an MBA from Harvard University and has a Bachelor of Arts in Public Policy from Michigan State University, USA.
Outside mandates
Listed companies:
- Member of the Board of Directors of LivaNova Inc.
Other mandates:
- Chair of the Board of Directors of Cala Health
- Executive Chair of the Board of Directors of Contego Inc.
- Member of the Board of Directors of Corza Inc.
- Member of the Board of Directors of Imperative Care
- Operating Partner of Lightstone Ventures

Gilbert Achermann
(born 1964, Swiss citizen) has been a non-executive member of the Board of Directors since 2024.
Gilbert Achermann served as Chair of the Board of Directors of the Straumann Group from 2010 until 2024. Before that, he was Straumann Groupʼs CFO and later CEO totaling up to more than 12 years, during which time he played a central role in building the company into a global leader in the dental industry. In 2020, he became a member, and in 2022 the Chair of the Board of Directors of Ypsomed Group. Since 2022 Gilbert Achermann is a member of the Board of Directors of Unilabs, and since 2023 its Chair. Since 2022 he is also a member of the Board of Directors of Greentech, a start-up company.
Since 2018 he serves on the Board of IMD in Lausanne and has been elected Vice Chair as of 2026. Since 2020, Gilbert Achermann is also a member and since 2024 Vice President of the Management Board of the Swiss Medtech Association. From 2012 until 2024, he served on the Board of Directors of Julius Baer Group.
With his extensive international business and executive experience, along with a profound understanding of the MedTech industry paired with his long-standing tenure as Chair of the Board of Directors at various companies, he provides valuable insights to the Board of Directors.
Gilbert Achermann holds a degree in Business Administration from the University of Applied Science in St. Gallen and completed the Executive MBA program at the IMD in Lausanne, Switzerland.
Outside mandates
Listed companies:
- Chair of the Board of Directors of Ypsomed Group
Other mandates:
- Chair of the Board of Directors of Unilabs Group
- Member of the Board of Greentech
- Designated Vice Chair of the Supervisory Board of IMD Lausanne
- Vice Chair of the SwissMedtech Association

Gregory Behar
Gregory Behar (born 1969, Swiss citizen) has been a non-executive member of the Board of Directors since 2021.
Since January 2024 he is the CEO of Recipharm AB, a leading Contract Development and Manufacturing Organization (CDMO) in the pharmaceutical industry. From 2014 until December 31, 2023, he served as CEO of Nestlé Health Science, a global leader in the science of nutrition, and became a member of the Nestlé Executive Board in 2017. From 2011 to 2014, he was President & CEO of Boehringer Ingelheim Pharmaceuticals Inc. (USA). Prior to that, he held various leadership positions with Boehringer Ingelheim GmbH (Germany), Novartis AG, and Nestlé SA.
With his broad international business and executive experience in the healthcare industry as well as his strong track record in leading successful global businesses, Gregory Behar brings valuable insight to the Board of Directors.
Gregory Behar earned an MBA from INSEAD, France, a Master of Science in mechanical engineering and manufacturing from EPFL Lausanne, Switzerland, and a Bachelor of Science in mechanical engineering from the University of California in Los Angeles, USA.
Outside mandates
Listed companies:
- n.a.
Other mandates:
- CEO of Recipharm AB
- Member of the Board of Directors of Amazentis SA
- Member of the Board of Directors of New Biologix (mandate held at the direction of Recipharm AB as part of his role as its CEO and thus, shall not be considered as an additional outside mandate)

Lynn Dorsey Bleil
(born 1963, US citizen) has been a non-executive member of the Board of Directors since 2016 and serves as a member of the Audit Committee.
She retired as Senior Partner (Director) from McKinsey & Company in the US in 2013 after more than 25 years of advising senior management and boards of leading healthcare companies on corporate and business unit strategy, mergers and acquisitions, and public policy across all segments of the healthcare value chain. She was also a member of the Board of Directors of Auspex Pharmaceuticals until its sale to Teva in March 2015, of DST Systems until its sale to SS&C in April 2018, and of Stericycle Inc. until its sale to Waste Management in November 2024.
With her extensive experience in advising North American healthcare companies across the entire value chain and through her various board mandates in this sector, she brings very valuable strategic perspectives to the Group and contributes her broad know-how as a Board member.
Lynn Dorsey Bleil holds a Bachelorʼs degree in Chemical Engineering from Princeton University and a Masterʼs degree in Business Administration from the Stanford University Graduate School of Business, USA.
Outside mandates
Listed companies:
- Member of the Board of Directors of Alcon Inc..
- Member of the Board of Directors of Amicus Therapeutics Inc.
Other mandates:
- Chair of the Intermountain Healthcare Wasatch Back Hospitals Community Board (a non-profit organization)

Lukas Braunschweiler
(born 1956, Swiss citizen) was the CEO of the Sonova Group from November 2011 until March 31, 2018 and has been a non-executive member of the Board of Directors since 2018 and serves as member of the Nomination and Compensation Committee.
Before joining the company, Lukas Braunschweiler was CEO of the Swiss technology group RUAG from 2009 until 2011. From 2002 to 2009, as President and CEO, he headed the Dionex Corporation. The California-based company, active in the life sciences industry, was listed on the Nasdaq stock exchange. Previously, from 1995 to 2002, he held various group executive positions in Switzerland and the US for Mettler Toledo, a precision instruments manufacturer.
Lukas Braunschweiler brings broad CEO experience from a variety of tech-oriented companies and industries in an international environment. Having served as CEO of Sonova from 2011 to 2018, he has not only a comprehensive knowledge of Sonova as a company and its business but also a broad experience in the global hearing aid industry.
Lukas Braunschweiler received a Master of Science in analytical chemistry (1982) and was awarded a Ph.D. in physical chemistry (1985) from the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland.
Outside mandates
Listed companies:
- Chair of the Board of Directors of Tecan Group AG
Other mandates:
- n.a.

Roland Diggelmann
(born 1967, Swiss citizen) has been a non-executive member of the Board of Directors since 2021 and serves as a member and Chair on the Nomination and Compensation Committee.
From 2019 until March 31, 2022, he has been CEO of Smith & Nephew plc, a UK-based leading global medical technology company active in orthopedics, sports medicine, and advanced wound management. From 2008 to 2012 he was managing director for the Asia/Pacific region and from 2012 until 2018 CEO of Roche Diagnostics. He previously held senior management positions in sales and marketing as well as strategic planning at Zimmer Holdings and Sulzer Medica (later known as Centerpulse).
With more than 20 years of executive experience in the medical device and life sciences industry across many parts of the world and as CEO, Roland Diggelmann provides valuable input to the implementation of Sonovaʼs strategy.
Roland Diggelmann studied Business Administration at the University of Bern, Switzerland.
Outside mandates
Listed companies:
- Chair of the Board of Directors of Mettler Toledo International Inc.
Other mandates:
- Member of the Board of Directors Berlin Heals AG
- Member of the Board of Directors of HeartForce AG
- Member of the Board of Directors Navignostics AG
- Member of the Board of Directors Osler Diagnostics Ltd.
_width-1240.jpeg)
Julie Tay
(born 1966, Singapore citizen) has been a non-executive member of the Board of Directors since 2022 and serves as a member on the Nomination and Compensation Committee.
She served as Senior Vice President and Managing Director, Asia Pacific in Align Technology Inc from 2013 to 2022. She was also a member of the global Executive Management Committee. Align Technology is a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry.
Before that she held various management positions at Bayer Healthcare, JohnsonDiversey, and Johnson & Johnson Medical. With her broad executive experience in the medical device industry and her executive experience, Julie Tay brings valuable insight to the Board of Directors.
Julie Tay holds a BA from the National University of Singapore and an MBA in International Marketing from the Curtin University of Technology, Australia.
Outside mandates
Listed companies:
- Member of the Board of Directors of EBOS Group Ltd.
Other mandates:
- n.a.
_width-1240.jpeg)
Ronald van der Vis
(born 1967, Dutch citizen) has been a non-executive member of the Board of Directors since 2009 and serves as a member of the Audit Committee, which he chaired from 2019 to 2021.
Ronald van der Vis served as Group CEO of Esprit Holdings Limited, a global fashion and lifestyle company listed on the Hong Kong Stock Exchange, from 2009 until November 2012. Prior to this, since 1998, he held various general management positions at GrandVision NV, the worldʼs leading optical retailer. He was Group CEO at GrandVision NV from 2004 to 2009.
With his extensive international expertise in the retail sector and his broad M&A, corporate finance and strategic experience, Ronald van der Vis provides valuable input to the Groupʼs vertically integrated business strategy.
Ronald van der Vis graduated from the Nyenrode Business University in the Netherlands and received his Masterʼs degree in business administration from the Alliance Manchester Business School in the UK. He has gained significant financial expertise both through his education and through his business experience as CEO and private equity partner.
Outside mandates
Listed companies:
- n.a.
Other mandates:
- Operating Partner, Co-Investor and Industry Advisor
- Chair of the Supervisory Board of European Dental Group
- Chair of the Supervisory Board of Equipe Zorgbedrijven
- Chair of the Supervisory Board of United Veterinary Care
- Member of the Supervisory Board of HEMA BV

Adrian Widmer
(born 1968, Swiss citizen) has been a non-executive member of the Board of Directors since 2020 and serves as a member and Chair on the Audit Committee.
Since 2014 he is Group CFO of Sika AG, a global specialty chemical company based in Switzerland. He previously served as Head Group Controlling and M&A at Sika from 2007 to 2014. Prior to joining Sika, he held various management positions at BASF, Degussa and Textron Inc. in the areas of finance and controlling, business development and general management.
With his broad management background, his experience in M&A and business development, and particularly his financial expertise as active CFO, Adrian Widmer is well qualified to serve on and lead the Audit Committee as a financial expert and is an ideal sparring partner for Sonovaʼs CFO.
Adrian Widmer holds a Master of Science degree in Business and Economics from the University of Zurich, Switzerland and completed the Advanced Management Program of INSEAD Fontainebleau in France.
Outside mandates
Listed companies:
- Group CFO of Sika AG
Other mandates:
- n.a.
Internal organizational structure
Allocation of tasks within the Board of Directors
As specified in Art. 17 para. 1 of the Articles of Association, the Board of Directors constitutes itself, except for the Chair and the members of the Nomination and Compensation Committee, who must be elected by the shareholders. If the office of the Chair or a member of the Nomination and Compensation Committee is vacant, pursuant to Art. 16 para. 4 of the Articles of Association, the Board of Directors appoints a replacement from among its members for the remaining term of office. The duties of the Chair are set out in Art. 16 of the Organizational Regulations, and the duties of the Vice-Chair are set out in Art. 18 of the Organizational Regulations.
In accordance with Art. 13 para. a of the Organizational Regulations, which supplements the Articles of Association, the Board of Directors appoints an Audit Committee.
Tasks and areas of responsibility of Board of Directorsʼ committees
The duties and authorities of the committees are defined in the Articles of Association, the Organizational Regulations, and the Board Committee Charters (available for the Audit Committee and the Nomination and Compensation Committee).
The committees usually meet before the Board of Directorʼs meetings, report regularly on activities and make proposals to the Board of Directors based on their findings. The overall responsibility for duties delegated to the committees remains with the Board of Directors.
Audit Committee
The members of the Audit Committee are Adrian Widmer (Chair), Gregory Behar, Lynn Dorsey Bleil and Ronald van der Vis.
The duties of the Audit Committee include reviewing the performance and effectiveness of external and internal audits on behalf of the entire Board of Directors; evaluating the companyʼs financial control systems, financial structure, and risk management control mechanisms; and verifying the interim and annual accounts and financial statements of the Sonova Group. The Audit Committee is also kept regularly informed on the companyʼs compliance program. Further details can be found in the Audit Committee Charter.
The Audit Committee meets as often as required but no fewer than four times per year. During the reporting period, the Audit Committee met four times. The Chair of the Board of Directors was invited to, and attended, every Audit Committee meeting as a guest.
Nomination and Compensation Committee
The members of the Nomination and Compensation Committee are Roland Diggelmann (Chair), Lukas Braunschweiler, Stacy Enxing Seng, and Julie Tay.
The Nomination and Compensation Committee supports the mission of the Board of Directors to attract, retain, and motivate people with outstanding professional and human capabilities at the Board of Directors and top management levels. In the selection and nomination processes, the committee considers independence, expertise, experience, and skills (including those related to economic, environmental and social aspects) needed for the respective corporate bodyʼs tasks, seeking where possible to establish balance in diversity terms including but not limited to: gender, age, nationalities or country of origin, ethnicity, competencies, experiences, ways of believing and mindsets. The Nomination and Compensation Committee also supports the Board of Directors in preparing the compensation report, establishing and reviewing the companyʼs compensation principles, guidelines, and performance metrics, and preparing proposals to the Annual General Shareholdersʼ Meeting on the compensation of the Board of Directors and Management Board. The committee may also submit proposals and recommendations to the Board of Directors on other compensation-related issues. Further details can be found in the Nomination and Compensation Committee Charter.
The Nomination and Compensation Committee meets as often as required but no fewer than four times per year. During the reporting period, the committee met four times and held two additional conference calls on relevant subject matters. The Chair of the Board of Directors was invited to, and attended, every Nomination and Compensation Committee meeting as a guest.
Working methods of the Board of Directors and its committees
During the reporting period, the Board of Directors held five regular meetings and one additional conference call on relevant subject matters. The table below shows the individual membersʼ attendance at Board of Directors and committee meetings, as well as the average length of the meetings:
BoD meetings | 1) | BoD add. calls | 2) | AC meetings | 3) | AC add. calls | 4) | NCC meetings | 5) | NCC add. calls | 6) | |||||||
No. of meetings in 2024/25 | 5 | 1 | 4 | 1 | 5 | 1 | ||||||||||||
Robert F. Spoerry | 5 | 1 | 4 | 7) | 5 | 7) | 1 | 7) | ||||||||||
Stacy Enxing Seng | 5 | 1 | 5 | 1 | ||||||||||||||
Gilbert Achermann | 5 | 8) | 1 | |||||||||||||||
Gregory Behar | 5 | 1 | 4 | 1 | ||||||||||||||
Lynn Dorsey Bleil | 5 | 1 | 4 | 1 | ||||||||||||||
Lukas Braunschweiler | 5 | 1 | 5 | 1 | ||||||||||||||
Roland Diggelmann | 5 | 1 | 5 | 1 | ||||||||||||||
Julie Tay | 5 | 1 | 5 | 1 | ||||||||||||||
Ronald van der Vis | 5 | 1 | 4 | 1 | ||||||||||||||
Adrian Widmer | 5 | 1 | 4 | 1 | ||||||||||||||
Average meeting length | 8.5 | h | 1 | h | 3 | h | 1 | h | 2 | h | 1 | h |
1)Regular Board of Directors meetings in person.
2)Additional calls of the Board of Directors.
3)Regular meetings of the Audit Committee (AC) in person.
4)Additional calls of the Audit Committee (AC).
5)Regular meetings of the Nomination and Compensation Committee (NCC) in person.
6)Additional calls of the Nomination and Compensation Committee (NCC).
7)As a guest.
8)Participated in two meetings as a guest before being elected at the 2024 AGM.
Urgent business matters were discussed in various telephone conferences. In addition to formal meetings at which minutes were taken, members of the Board of Directors or the committees also frequently met informally for other topics and discussions that required additional time. These included but were not limited to, preparations for formal meetings, interviews, nomination of key individuals, and reviewing M&A projects.
The agenda for a meeting of the Board of Directors or of a Board committee is set by its respective Chair. Any member of the Board of Directors or a committee may request a meeting or ask that an item be put on the agenda. Members of the Board of Directors and the committees are provided in advance of meetings with all relevant documents that enable them to prepare for the discussion of the agenda items during the meeting. The Board of Directors and its committees constitute a quorum if at least half of the members are present. The Board of Directors and its committees approve resolutions by a majority of members present at the meeting. In the event of an equal number of votes, the Chair has the casting vote.
The Board of Directors works closely with the Management Board. In general, the meetings of the Board of Directors and its committees are also attended by the CEO and the CFO and, depending on the agenda, other members of the Management Board. The Board of Directors and the committees meet in an executive session after every Board and committee meeting, respectively. The Board of Directors consults external experts in connection with specific tasks when necessary.
During the 2024/25 financial year, the five regular meetings of the Board of Directors were attended by the CEO and other members of the Management Board to review, amongst other topics, performance against plan, key initiatives, and strategic matters. If necessary, the Board of Directors also consults with other internal experts (such as the Group General Counsel) or external advisors.
All four meetings of the Audit Committee were attended by the Chair as a guest. The CEO, the CFO, and the Head of Internal Audit and Risk participated in all four meetings of the Audit Committee. Representatives of the auditors participated in one out of these four meetings.
All five meetings of the Nomination and Compensation Committee were attended by the Chair as a guest and were held in the presence of the CEO and the Group Vice President Corporate Human Resources.
Definition of areas of responsibility
The Board of Directors of Sonova Holding AG is responsible for the overall direction of the company, except in matters reserved by law to the Annual General Shareholdersʼ Meeting. The Board of Directors decides on all matters that have not been reserved for or conferred upon another governing body of the company by law, by the Articles of Association, or by the companyʼs Organizational Regulations. The division of responsibility between the Board of Directors and the Management Board is set out in detail in the companyʼs Organizational Regulations.
Information and control instruments vis-à-vis the Management Board
The Management Board reports regularly to the Board of Directors and its committees. At each Board of Directorsʼ meeting, the Management Board informs the Board of Directors on the status of current business matters and financial results, and presents relevant strategic initiatives as well as major business transactions such as M&A. Each year a Board of Directorsʼ meeting is reserved for the presentation and discussion of the companyʼs strategy and long-term financial plan. The Board of Directors is provided with monthly consolidated sales reports containing data on revenue, average selling prices, and units for each major product, subsidiary, and market. The Board of Directors also receives, on a monthly basis, the financial report with the full profit and loss statement, the balance sheet, and the cash flow statement, as well as the CEOʼs report on business performance, the competitive situation, updates on various initiatives, and an outlook. Telephone conferences are held as required between the members of the Board and the CEO or CFO. Furthermore, each member of the Board of Directors may request information on all matters concerning the company.
Internal audit, risk, and compliance
The mandates of the Internal Audit and Risk Management functions, along with their reporting lines and scope of activities, are defined in the Internal Audit & Risk Charter approved by the Audit Committee and the Board of Directors. Internal Audit carries out compliance and operational audits and assists the business units in attaining their goals by providing assurance from an independent evaluation of the effectiveness of internal control processes. The Management is responsible for the control of business risks and for compliance with laws and regulations. The Audit Committee approves the annual work plans of Internal Audit and ensures that the relevant Group companies are adequately reviewed according to their risk scoring. The Audit Committee also reviews and discusses the reports on completed audits submitted by Internal Audit. Internal Audit, together with Business Controlling, monitors the implementation by Group companies of any measures necessary to address findings from previous audits, and regularly reports progress to the Audit Committee. The Head of Internal Audit & Risk reports to the Chair of the Audit Committee. In addition, the Chair of the Board of Directors is invited to the Audit Committee as a guest and is thus kept fully informed, but has no voting rights.
The Group has implemented an efficient and comprehensive system to identify and assess strategic, operational, financial, legal, cyber, and compliance risks related to the Groupʼs business activities. Risk management and mitigation proposals are prepared by the Management Board, reviewed by the Audit Committee and subsequently approved by the entire Board of Directors. The risk management function categorizes risks by severity and probability and supports the Management Board in determining the measures necessary to address or mitigate them. Our risk management approach is aligned with international standards, such as the Committee of Sponsoring Organizations (COSO) internal control framework.
The Board of Directors approves the risk assessment and provides guidance from a strategic point of view. To continuously monitor key risks and their mitigation, Risk Management prepares risk status reports which are presented to the Audit Committee on an ad hoc basis.
Risk Management also assumes responsibility for the Internal Control System (ICS) for financial reporting risks. The Board of Directors receives annual updates on the Group companiesʼ compliance with the ICS guidelines.
The Group compliance program supports Sonovaʼs core values of ethical behavior and unquestionable integrity. The program is administered by the Head Group Compliance & Data Privacy and ultimately overseen by the Group General Counsel. Among other activities, the program administers the ethics hotline, and other reporting channels and ensures that reports are adequately addressed; structures the policy framework for ethical business conduct and trains the businesses on it; counsels and advises on proposed business approaches; and supports the businesses in their vetting of business partners. Quarterly compliance reports are provided to the Audit Committee and an annual compliance report is addressed to the Board of Directors. The Group General Counsel has an activity-specific or “dotted-line” reporting relationship to the Chair of the Audit Committee with respect to compliance responsibilities.
Environmental, Social and Governance Management (ESG)
Sonovaʼs environmental, social and governance (ESG) strategy is integrated into its overall strategy and is an essential part of Sonovaʼs way of doing business. “We take accountability” is one of our core values: ESG improvement indicators are therefore embedded throughout our business, and we strive to optimize them with the same intensity as we do our financial ones, making significant efforts and setting ambitious targets.
Sonova has established an ESG Council, which oversees and further develops the Groupʼs ESG strategy, including commitments and targets, and monitors progress on key performance indicators and initiatives. The ESG Council meets at least on a quarterly basis and consists of the Group CEO, selected members of the Management Board, the Group General Counsel, and the Corporate Sustainability team. Progress on ESG targets is also regularly reviewed by the full Management Board and ESG targets are an element of each Management Board memberʼs variable compensation. The Audit Committee regularly reviews the data collection and reporting consolidation of ESG targets, while the Nomination and Compensation Committee reviews the achievement of ESG targets as part of determining the variable compensation. The Board of Directors approves the ESG strategy, initiatives, and targets, and regularly receives progress updates from the Management Board (see the comprehensive ESG Report).
Some of the key ESG topics at Sonova include climate change, access to hearing care, product quality, -reliability, and -safety, talent management, data privacy, and digital ethics. Among other reports, a comprehensive D&I report including initiatives and specific targets is prepared by the CEO and Corporate Human Resource Management and reviewed annually by the entire Board of Directors.
Responsible behavior also includes full compliance with tax laws and regulations at all times. Sonovaʼs tax principles provide high level information on procedures and internal guidelines for tax compliance throughout the Sonova Group.
Good governance is supported by a regular dialogue on ESG topics with proxy advisors, investors, and rating agencies, and by Sonovaʼs continuously active risk management and our compliance functions.